Irbesartan in hypertension and type 2 diabetes mellitus
https://doi.org/10.18705/1607-419X-2011--2-
Abstract
Arterial hypertension and type 2 diabetes mellitus often go together. This «criminal duet» leads to a significant increase of the risk of both micro- and macrovascular complications. The angiotensin receptors antagonists, and, in particular, Irbesartan, take the leading position among all classes of antihypertensive drugs in the treatment of arterial hypertension combined with diabetes mellitus.
About the Authors
Yu. Sh. Khalimov
Military Medical Academy named after S.M. Kirov, St Petersburg
Russian Federation
Russian Federation
S. V. Gaiduk
Military Medical Academy named after S.M. Kirov, St Petersburg
Russian Federation
Russian Federation
References
1. Sountsov Y.I., Dedov I.I., Shestakova M.V. Screening of diabetes mellitus complication as a method to evaluate the quality of patient care / Ministry of Health and Social Development of the Russian Federation, FSE Research Centre of Endocrinology. - 2008. - P. 52.
2.
3. Коровин К.А. Шаляпин. Встречи и совместная жизнь. - СПб.: «Азбука», 2010. - 224 с.
4.
5. Шестакова М.В., Дедов И.И. Сахарный диабет и хроническая болезнь почек. - М.: ООО «Медицинское информационное агентство», 2009. - 482 с.
6.
7. Dickinson H.O., Mason J.M., Nicolson D.J. et al. Lifestyle interventions to reduce raised blood pressure: a systematic review of randomized controlled trials // Hypertension. - 2006. - Vol. 24, № 2. - P. 215-233.
8.
9. Bramlage P., Durand-Zaleski I., Desai N. et al. The value of irbesartan in the management of hypertension // Expert Opin. Pharmacother. - 2009. - Vol. 10, № 11. - P. 1817-1831.
10.
11. Fogari R., Ambrosoli S., Corradi L. et al. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring: Irbesartan Multicenter Investigators' Group // Hypertension. - 1997. - Vol. 15, № 12. - P. 1511-1518.
12.
13. Benson S.C., Pershadsingh H., Ho C. et al. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ- modulating activity // Hypertension. - 2004. - Vol. 43, № 5. - P. 993-1002.
14.
15. Ichiki T., Tian Q., Imayama I., Sunagawa K. Telmisartan manifests powerful anti-inflammatory effects beyond class effects of angiotensin II type 1 blocker by inhibiting tumor necrosis factor α-induced interleukin 6 expressions through peroxisome proliferator activated receptor γ activation // Circulation. - 2008. -Vol. 118. - P. 513.
16.
17. Bramlage P., Pittrow D., Kirch W. The effect of irbesartan in reducing cardiovascular risk in hypertensive type 2 diabetic patients: an observational study in 16,600 patients in primary care // Curr. Med. Res. Opin. - 2004. - Vol. 20, № 10. - P. 1625-1631.
18.
19. Lewis E.J., Hunsicker L.G., Clarke W.R. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes // N. Engl. J. Med. - 2001. - Vol. 345, № 12. - P. 851-860. 12)
20.
21. ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial // Lancet. - 2006. - Vol. 367, № 9526. - P. 1903-1912.
22.
23. Baumhakel M., Schlimmer N., Bohm M. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome // Int. J. Impot. Res. - 2008. - Vol. 20, № 5. - P. 493-500.
24.
25. Calkin A.C., Thomas M.C. PPAR agonists and cardiovascular disease in diabetes // Hindawi Publishing Corporation PPAR Research. - 2008. - 12 р.
Review
For citations:
Khalimov Yu.Sh., Gaiduk S.V. Irbesartan in hypertension and type 2 diabetes mellitus. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2011;17(2):189-194. (In Russ.) https://doi.org/10.18705/1607-419X-2011--2-
Views:
1054
Email this article 